Lates News

Every AI Express News, Huaan Securities released a research report on August 25th, giving Yifan Pharmaceuticals (002019.SZ) a buy rating. The main reasons for the rating include: 1) improving operation efficiency and reducing costs, leading to a significant growth in operating cash flow; 2) Yilishu continues global commercialization efforts, anchoring its overseas strategy; 3) Data disclosure on Duanjin Jiedu Capsule 1b shows significant effects in preventing relapse. (Daily Economic News)